Welcome

OWL is a biotechnology company in the field of Metabolomics with pioneering diagnostics products and unique R&D services for the scientific community.

Metabolomics uncovers metabolic alterations in biological samples and provides an overall picture of human or animal health: The information on complex biochemical processes obtained is highly valuable in drug mechanism and toxicology studies, biomarker discovery and the optimization of biotechnological processes.

OWL´s two business lines stem from our in depth knowledge of metabolomics and liver diseases.

DIAGNOSTIC PRODUCTS:

"OWLiver Test" is the first "in vitro" test for determining steatosis and NASH.
The company also develops diagnostic markers research for high prevalence diseases.

R&D SERVICES:

OWL applies its expertise in metabolomics and lipidomics to provide services to the pharmaceutical, food and cosmetics industries, as well as research centers, biotech companies and CROs.

 

Company introduction

  • OWLiver - information for physicians - how it works
  • owl liver for patients - that is it - benefits - faqs
  • what is metabolomics - get to know owl technology
Events
News

06/07/2017

News

ProSciento and OWL Metabolomics Form Strategic Collaboration Focused on Accelerating NAFLD/NASH Clinical Trial Recruitment
ProSciento and OWL Metabolomics announced an exclusive, multi-year collaboration aimed at identifying individuals who are eligible for enrollment into clinical trials of therapeutic candidates to treat NAFLD and NASH using OWL?s non-invasive, lipidomics-based diagnostic assays.

 

05/04/2017

News

OWL Metabolomics and Sanyal Biotechnology LLC Announce Strategic Partnership with Overseas Expansion
OWL Metabolomics is planning to open its American office in the VABeachBio biotechnology incubator in Virginia Beach, USA, co-locating with Sanyal Biotechnology; likewise, Sanyal Biotechnology is planning to open its European office under the auspices of OWL in its location in Bilbao, Spain.
By this agreement, made at last ILC /EASL Congress in Amsterdam, the two companies will share resources in their respective locations as they combine efforts to better serve their pharmaceutical clients.

 

04/06/2017

News

OWL Metabolomics will participate in the International Liver Congress 2017, the 52nd annual meeting of the European Association for the Study of the Liver.
This year´s participation includes 3 scientific abstracts and a mini workshop. The abstracts will focus on the elucitation of the mode of action of Aramchol, and on liquid biopsy for NAFLD diagnosis, staging and management, together with NASH subtype identification. The workshop program will highlight the use of metabolomics within NASH diagnosis in clinical trials, in type 2 diabetes mellitus and in bariatric surgery.

 

OWL is a trading name of
ONE WAY LIVER, S.L
Parque Tecnológico de Bizkaia
Edificio 502 - Planta 0
48160 Derio - Bizkaia - Spain
Phone: +34 94 431 85 40
Fax: +34 94 431 71 40

With this web OWL intends to provide users with information to better understand their health and their diagnosed illnesses. You should consult with a
qualified physician for diagnosis and for answers to your personal questions/circunstances.
Last update: 06/08/2017

With the collaboration of: